Intellia Therapeutics, Inc.
NTLA- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0001652130
In the last 90 days, Intellia Therapeutics, Inc. insiders filed 0 open-market purchases and 4 sales; 329 institutions reported holding it in 13F filings for Q2 2026, worth $2.43B in total; ARK Invest is the only superinvestor holding it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $506.6K in total
- 4
- 13F holdersQ2 2026, +25 vs. previous quarter
- 329
- 13F valueReported value at the end of Q2 2026
- $2.43B
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Superinvestors holding NTLA, Q2 2026
1 superinvestor reports holding Intellia Therapeutics, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
ARK Invest
Cathie Wood
1.9%
Intellia Therapeutics, Inc.'s share of the portfolio
- Shares
- 16,875,684
- Value
- $285.5M
Latest insider trades
Open-market purchases and sales by Intellia Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 24, 2026 (view filing)4:05 PM ET | Aug 20-21 | 4 days | Leonard John MPresident and CEO | SSale | −22.7K | $12.65 | −$286.8K | −1.9%1.15M after | 2 lots10b5-1 |
| Jul 24, 2026 (view filing)5:26 PM ET | Jul 22 | 2 days | Dulac Edward J IIIEVP, Chief Financial Officer | SSale | −8.11K | $11.25 | −$91.2K | −5.2%148.2K after | |
| Jul 6, 2026 (view filing)5:02 PM ET | Jul 1 | 5 days | Dube Michael PVP, Chief Accounting Officer | SSale | −2.64K | $16.78 | −$44.3K | −3.8%66.9K after | |
| Jul 6, 2026 (view filing)5:01 PM ET | Jul 2 | 4 days | Dulac Edward J IIIEVP, Chief Financial Officer | SSale | −4.68K | $18.00 | −$84.2K | −2.9%156.3K after | 10b5-1 |
| Mar 3, 2026 (view filing) | Mar 2 | 1 day | Basta JamesEVP, General Counsel | SSale | −1.21K | $13.78 | −$16.7K | −0.8%156.8K after | |
| Mar 3, 2026 (view filing) | Mar 2 | 1 day | Clark ElianaEVP, Chief Technical Officer | SSale | −607 | $13.78 | −$8.36K | −0.6%93.9K after | |
| Jan 7, 2026 (view filing) | Jan 5 | 2 days | Leonard John MPresident and CEO | SSale | −34.1K | $9.21 | −$314.5K | −3.3%1.01M after | |
| Jan 7, 2026 (view filing) | Jan 5 | 2 days | Schultes Birgit CEVP, Chief Scientific Officer | SSale | −8.51K | $9.21 | −$78.4K | −7.9%98.5K after | |
| Jan 7, 2026 (view filing) | Jan 5 | 2 days | Basta JamesEVP, General Counsel | SSale | −10.4K | $9.21 | −$95.8K | −9.3%101.5K after | |
| Jan 7, 2026 (view filing) | Jan 5 | 2 days | Cohen Fred EDirector | PPurchase | +150.0K | $9.35 | +$1.40M | +261.1%207.5K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Intellia Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| ARK Investment Management LLCSuperinvestorARK Invest | 16,875,684 | $285.5M | 1.85% | +2,366,437+16.3% | Added |
| BlackRock, Inc. | 15,409,023 | $260.7M | 0.00% | +3,253,217+26.8% | Added |
| State Street Corp | 9,234,987 | $156.3M | 0.00% | +2,312,311+33.4% | Added |
| Vanguard Portfolio Management LLC | 7,332,401 | $124.1M | 0.01% | +1,109,076+17.8% | Added |
| D. E. Shaw & Co., Inc. | 6,443,323 | $109.0M | 0.07% | +715,146+12.5% | Added |
| Vanguard Capital Management LLC | 6,028,586 | $102.0M | 0.00% | +944,481+18.6% | Added |
| Two Sigma Investments, LP | 5,235,348 | $88.6M | 0.07% | +529,447+11.3% | Added |
| FMR LLC | 4,773,034 | $80.8M | 0.00% | +2,705,812+130.9% | Added |
| Ra Capital Management, L.P. | 4,526,926 | $76.6M | 0.67% | +4,526,926 | New |
| Regeneron Pharmaceuticals, Inc. | 3,702,995 | $62.7M | 35.35% | 00.0% | Unchanged |